Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims:

1. (Previously Presented) A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



(I)

wherein -N-HET is



(Id)

Q is



Q1 or



Q2

R_2 and R_3 are independently selected from H, F, Cl, CF_3, OMe, SMe, Me and Et;

T is selected from the groups in (TAa1) to (TAa12):



(TAa1)



(TAa5)



(TAa7)



(TAa8)

wherein :

R^{6h} is hydrogen or (1-4C)alkyl;

R^{4h} and R^{5h} are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with ORc (wherein Rc is $R^{13}CO$ and R^{13} is selected from Rc2b), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

(Rc2b) (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)$(OH)_2$, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P$(OH)_2$ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)$(OH)_2$, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphinate [-P$(OH)_2$ and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)$_p$NH-, (1-4C)alkylS(O)$_p$-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)$_p$NH-, fluoro(1-4C)alkylS(O)$_p$((1-4C)alkyl)N-, (1-4C)alkylS(O)$_q$- [the (1-4C)alkyl group of (1-4C)alkylS(O)$_q$- being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)$(OH)_2$, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P$(OH)_2$ and mono- and di-(1-4C)alkoxy derivatives

thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)$_p$NH-, (1-4C)alkylS(O)$_p$-((1-4C)alkyl)N-, and (1-4C)alkylS(O)$_q$-.

2. (Previously Presented) The compound of claim 1, wherein Q is Q1.

3. (Cancelled)

4. (Previously Presented) The compound of claim 1, wherein R^2 and R^3 are independently hydrogen or fluoro.

5. (Cancelled)

6. (Currently amended) The compound of claim 1, which is a compound of formula (IB)



(IB)

wherein ~~N-HET is 1,2,3-triazol-1-yl or tetrazol-2-yl;~~
R^2 and R^3 are independently hydrogen or fluoro;
R^{6h} is hydrogen or (1-4C)alkyl;
R^{4h} and R^{5h} are independently selected from hydrogen, cyano, hydroxy(1-4C)alkyl, cyano(1-4C)alkyl, phosphoryl(1-4C)alkyl, benzyl (optionally substituted on the phenyl ring by one substituent selected from halo, methyl and methoxy), (1-4C)alkyl, (1-4C)alkyl substituted with ORc (wherein Rc is $R^{13}CO$ and R^{13} is selected from Rc2b), (1-4C)alkanoyl and (1-4C)alkoxycarbonyl.

7. (Cancelled)

8. (Previously Presented) A method for producing an antibacterial effect in a warm blooded

animal which comprises administering to said animal an effective amount of a compound of claim 1.

9 – 10. (Cancelled)

11. (Previously Presented) A pharmaceutical composition which comprises a compound of claim 1, and a pharmaceutically-acceptable diluent or carrier.

12. (Original) A process for the preparation of a compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salts or in-vivo hydrolysable esters or pro-drugs thereof, which process comprises one of processes **(a)** to **(g)**:

(a) by modifying a substituent in, or introducing a new substituent into, the substituent group Q of another compound of formula (I) ; or

(b) by reaction of a compound of formula (II) :



(II)

wherein Y is a displaceable group with a compound of the formula (III) :

-N-HET

(III)

wherein –N-HET (of formula (Ia) to (If) optionally protected) is HN-HET (free-base form) or N-HET anion formed from the free base form; or

(c) by reaction of a compound of the formula (IV) :

Q-Z

(IV)

wherein Z is an isocyanate, amine or urethane group with an epoxide of the formula (V) wherein the epoxide group serves as a leaving group at the terminal C-atom and as a protected hydroxy group at the internal C-atom; or with a related compound of formula (VI) where the hydroxy group at the interna C-atom is protected and where the leaving group Y at the terminal C-atom is a leaving group;



(V) (VI)

or

(d) (i) by coupling, using catalysis by transition metals, of a compound of formula (VII) :



(VII)

wherein Y' is a group –N-HET as hereinbefore defined, X is a replaceable substituent;
with a compound of the formula (VIII), or an analogue thereof, which is suitable to give a T substituent as defined by (TAa1-TAa12) in which the link is via an sp^2 carbon atom (D = CH=C-Lg where Lg is a leaving group; or as in the case of reactions carried out under Heck reaction conditions Lg may also be hydrogen)



(VIII)

where T_1 and T_2 may be the same or different and comprise a precursor to a ring of type T as hereinbefore defined, or T_1 and T_2 may together with D form a ring of type T as hereinbefore defined;

(d) (ii) by coupling, using catalysis by transition metals, of a compound of formula (VIIA):



(VIIA)

wherein Y' is a group HET as hereinbefore defined, with a compound

[Aryl]-X

where X is a replaceable substituent;

(e) Where N-HET is 1,2,3-triazole by cycloaddition via the azide (wherein Y in (II) is azide), with acetylene or masked acetylene;

(f) Where N-HET is 1,2,3-triazole by synthesis with a compound of formula (IX), namely the arenesulfonylhydrazone of acetaldehyde, by reaction of a compound of formula (II) where Y = NH_2 (primary amine);



(II : Y = NH2)



(IX)

(g) Where N-HET is 1,2,3-triazole by cycloaddition via the azide (wherein Y in (II) is azide) with acetylene using Cu(I) catalysis in to give the N-1,2,3-triazole;



(II : Y = N_3)

and thereafter if necessary :

i) removing any protecting groups;

ii) forming a pro-drug (for example an in-vivo hydrolysable ester); and/or

iii) forming a pharmaceutically-acceptable salt.

13. (Previously Presented) A compound which is

(5*R*)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

Ethyl 5-{2-fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}isoxazole-3-carboxylate;

(5*R*)-3-{3-Fluoro-4-[3-(hydroxymethyl)isoxazol-5-yl]phenyl}-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-

yl]phenyl}isoxazol-3-yl)methyl dihydrogen phosphate;

1-Methyl-3-{4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-pyrazole-5-carbonitrile;

1-Methyl-3-{4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-pyrazole-5-carbaldehyde;

(5*R*)-3-[3-Fluoro-4-(1*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5*R*)-3-[3-Fluoro-4-(1-methyl-1*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5*R*)-3-[3-Fluoro-4-(2-methyl-2*H*-1,2,3-triazol-4-yl)phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(4-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-1*H*-1,2,3-triazol-1-yl)acetonitrile; or

(4-{2-Fluoro-4-[(5*R*)-2-oxo-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl}-2*H*-1,2,3-triazol-2-yl)acetonitrile.